DocWire News Editors

DocwireNews

In patients with heart failure with reduced ejection fraction (HFrEF), omecamtiv mecarbil significantly reduced the risk of the primary composite outcome of first HF event of cardiovascular (CV) death, according to data presented at a late-breaking science news briefing from the American Heart Association Scientific Sessions 2020.&ldquo;Selectively targeting the cardiac sarcomere with omecamtiv mecarbil, the first-in-class myotrope, is a novel approach to improving cardiac function,&rdquo; said John R. Teerlink, MD, of San Francisco VAMC/UCSF, who presented the results.&ldquo;The central defect in initiating factor in HFrEF is a decrease in systolic function,&rdquo; Dr. Teerlink explained. &ldquo;Yet, despite extensive investigative efforts for over a century no therapies for chronic HFrEF that targets this systolic dysfunction have improved patient outcomes and, in fact, most have actually increased mortality.&rdquo;Omecamtiv mecarbil is a is an investigational medication that was granted fast track designation by the FDA in May 2020. The drug binds to cardiac myosin, the protein in the heart that transforms chemical energy into mechanical work.The GALACTIC-HF trial randomly assigned 8,256 patients with symptomatic chronic HF with ejection fraction less than or equal to 35% to omecamtiv mecarbil plus standard HF therapy or placebo plus standard HF therapy. The median follow-up was 22 months.&ldquo;Participants&nbsp; in GALACTIC-HF represent one of the broadest ranges of HFrEF patients enrolled in contemporary HF trials,&rdquo; Dr. Teerlink said.The average age of patients was 66 years and the population was predominantly male and white.There was a significant 8% reduction in the risk for composite outcome of time to first HF event or CV death in patients assigned to omecamtiv mecarbil compared with placebo (HR=0.92; 95% CI, 0.86-0.99; P=.0025).The risk of a first HF event &mdash; a component of the primary outcome &mdash; was reduced by 7%, but did not reach statistical significance (HR=0.93; 95% CI, 0.86-1.00; P=.06). The risk for cardiovascular death alone was not significantly improved by omecamtiv mecarbil.To evaluate the potential impact of omecamtiv mecarbil on patient symptoms, the change in Kansas City Cardiomyopathy Questionnaire Total Symptom Score from baseline to week 24 was assessed. An overall joint test statistic P value of 0.028 did not meet the hierarchal multiplicity controlled threshold of 0.002. This secondary endpoint was not met.Subgroup analyses of the primary composite outcome demonstrated a consistent beneficial effect of omecamtiv mecarbil. However one subgroup &ndash; those with baseline LVEF 28% or less &ndash; demonstrated significant heterogeneity in treatment effect with a P value of 0.003 and a nominal 16% reduction in the primary endpointOmecamtiv mecarbil had no significant effect on blood pressure, renal function, or potassium homeostasis. There was no imbalance between the study arm in adverse events, serious adverse events of adverse events of special interest, including myocardial ischemia and ventricular arrhythmias.

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

GALACTIC-HF: Omecamtiv Mecarbil Reduced Risk of First HF Event, Death in HRrEF

AHA Scientific Sessions 2020

In patients with heart failure with reduced ejection fraction (HFrEF), omecamtiv mecarbil significantly reduced the risk of the primary composite outcome of first HF event of ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe